Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

机译：口服抗凝疗法治疗房颤患者的血脂异常和心血管事件的风险：ARISTOTLE（阿哌沙班减少卒中和其他血栓栓塞性心房颤动事件）试验的启示

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundDyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients with atrial fibrillation receiving oral anticoagulation.

机译：背景血脂异常是心血管事件的主要危险因素。脂蛋白对房颤患者的预后重要性尚不清楚。我们旨在探讨载脂蛋白A1（ApoA1）和B（ApoB）与口服抗凝治疗的房颤患者心血管事件之间的关系。

著录项

期刊名称 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
作者
Tymon Pol; Claes Held; Johan Westerbergh; Johan Lindbäck; John H. Alexander; Marco Alings; Cetin Erol; Shinya Goto; Sigrun Halvorsen; Kurt Huber; Michael Hanna; Renato D. Lopes; Witold Ruzyllo; Christopher B. Granger; Ziad Hijazi;
展开▼
作者单位

展开▼
年(卷),期 2018(7),3
年度 2018
页码 e007444
总页数 11
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
atrial fibrillation biomarkers cardiovascular disease cerebrovascular disease/stroke;

机译：心房颤动;生物标志物;心血管疾病;脑血管疾病/中风;

相似文献

外文文献
中文文献
专利

1. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial [J] . Garcia David A., Fisher Deborah A., Mulder Hillary, Autonomic neuroscience: basic & clinical . 2019,第1期

机译：用Apixaban或Warfarin治疗心房颤动患者的胃肠道出血：来自细胞腺癌的脑卒中和地心房颤动（亚里士多德）试验中的其他血栓栓塞事件的见解
2. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. [J] . Lars Wallentin, Ziad Hijazi, Ulrika Andersson, Circulation: An Official Journal of the American Heart Association . 2014,第21期

机译：生长分化因子15，一种氧化应激和炎症的标志物，用于房颤患者的风险评估：来自阿哌沙班减少房颤中风和其他血栓栓塞事件的见解（ARISTOTLE）试验。
3. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: Insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial [J] . HijaziZ., SiegbahnA., AnderssonU., Circulation: An Official Journal of the American Heart Association . 2014,第6期

机译：高敏感性肌钙蛋白I用于房颤患者的风险评估：阿哌沙班对房颤减少卒中和其他血栓栓塞事件的见解（ARISTOTLE）
4. Paroxysmal atrial fibrillation prediction using isolated premature atrial events and paroxysmal atrial tachycardia [C] . Thong, T., McNames, Engineering in Medicine and Biology Society, 2003. Proceedings of the 25th Annual International Conference of the IEEE . 2003

机译：阵发性房颤的预测使用孤立的早搏事件和阵发性房性心动过速
5. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for the prevention of stroke prophylaxis in atrial fibrillation. [D] . Harrington, Amanda. 2012

机译：阿哌沙班，达比加群，利伐沙班和华法林预防房颤预防中风的成本效益。
6. Correction: Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial [O] . 2021

机译：矫正：心房颤动患者血压控制和中风或全身栓塞的风险：中风血管和室心房颤动（亚里士多德）试验中的中风和其他血栓栓塞事件的结果
7. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial [O] . Tymon Pol, Claes Held, Johan Westerbergh, 2018

机译：口腔抗凝治疗治疗心房颤动患者的血吸虫血症和心血管事件的风险：亚里士多德的见解（APIXABAN用于降低中风和心房颤动的其他血栓栓塞事件）试验

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

摘要

著录项

相似文献

相关主题

期刊订阅